KURA
$30.05
Kura Oncology
$.52
1.76%
KURA
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.39)
Revenue:  $0.00 Mil
Thursday
Nov 5
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when KURA reports earnings?
Beat
Meet
Miss

Where is KURA's stock price going from here?
Up
Flat
Down
Stock chart of KURA
Analysts
Summary of analysts' recommendations for KURA
Score
Grade
Pivots
Resistance
$31.56
$30.88
$30.46

$29.78

Support
$29.36
$28.68
$28.26
Tweet
Growth
Description
Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California.